Halozyme Therapeutics Inc.

Halozyme Therapeutics uses its patented rHuPH20 hyaluronidase platform to enable subcutaneous delivery of biologics and small molecules, powering products such as Hylenex and Ocrevus, and benefiting from licenses with Roche, Pfizer and AbbVie.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 350
HQ: San Diego

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
HALO	Halozyme Therapeutics Inc. Cap: 8.5B \| P/E: 15.3	EQUITY	NMS	USD	US40637H1095	Active	📈